Vera Therapeutics (VERA) Change in Accured Expenses (2020 - 2026)

Vera Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$437000.0 for Q1 2026.

• Quarterly Change in Accured Expenses rose 90.86% year-over-year to -$437000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.8 million (up 358.67% YoY) and the FY2025 annual result came in at $14.4 million, up 100.92% from the prior year.
• Change in Accured Expenses was -$437000.0 for Q1 2026 at Vera Therapeutics, down from $7.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $8.1 million in Q2 2025 and bottomed at -$4.8 million in Q1 2025.
• A 5-year average of $1.5 million and a median of $474000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses slumped 2964.29% — and 2024, when it surged 776.68%.
• Vera Therapeutics' Change in Accured Expenses stood at $4.7 million in 2022, then plunged by 122.21% to -$1.1 million in 2023, then tumbled by 257.4% to -$3.8 million in 2024, then jumped by 291.35% to $7.2 million in 2025, then slumped by 106.06% to -$437000.0 in 2026.
• Business Quant data shows VERA's Change in Accured Expenses at -$437000.0 in Q1 2026, $7.2 million in Q4 2025, and $3.9 million in Q3 2025.